-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DN84IRyFdEcoMAnaiKjQR+eRvYj+PEXQktstLwy7pF0esySGiXYzAGRthxiuR4Va tSGZouSCf0C8AvBVXG3umQ== 0000899140-05-001152.txt : 20051227 0000899140-05-001152.hdr.sgml : 20051226 20051227140501 ACCESSION NUMBER: 0000899140-05-001152 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20051227 DATE AS OF CHANGE: 20051227 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IVAX CORP CENTRAL INDEX KEY: 0000772197 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 161003559 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09623 FILM NUMBER: 051286738 BUSINESS ADDRESS: STREET 1: 4400 BISCAYNE BLVD CITY: MIAMI STATE: FL ZIP: 33137 BUSINESS PHONE: 3055756000 MAIL ADDRESS: STREET 1: 4400 BISCAYNE BOULEVARD CITY: MIAMI STATE: FL ZIP: 33137 FORMER COMPANY: FORMER CONFORMED NAME: IVAX CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: IVACO INDUSTRIES INC DATE OF NAME CHANGE: 19871213 FORMER COMPANY: FORMER CONFORMED NAME: INLAND VACUUM INDUSTRIES INC DATE OF NAME CHANGE: 19870611 425 1 t3094920.txt PRESS RELEASE Filed by: Teva Pharmaceutical Industries Limited Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Companies: Ivax Corporation Commission File No. 001-09623 [GRAPHIC OMITTED] TEVA PHARMACEUTICALS USA - -------------------------------------------------------------------------------- Administrative Offices: TEVA PHARMACEUTICALS USA 1090 Horsham Road, PO Box 1090 North Wales, PA 19454-1090 - -------------------------------------------------------------------------------- Phone: (215) 591 3000 FAX: (215) 591 8600 December 22, 2005 Dear Option Holder: Concurrent with the effective date of the merger contemplated by the Agreement and Plan of Merger by and among IVAX Corporation, Teva Pharmaceutical Industries Limited ("Teva") and other parties, Teva will assume the IVAX Stock Option Plans together with all of the outstanding options granted under the Plans. In connection with the merger, all of the IVAX Options outstanding as of the effective time of the merger will become fully vested and will be converted to options (the "Teva Options") to purchase ordinary shares of Teva in the form of American Depositary Shares of Teva ("ADSs") evidenced by American Depositary Receipts. The ADSs are traded on the Nasdaq National Market ("NASDAQ"). The IVAX options will be converted to Teva Options using the exchange rate of .8471 as defined in the joint proxy/prospectus and the exercise price shall be correspondingly adjusted. Other than as noted above, your converted Teva Options will continue to have the same terms and conditions (including option periods and expiration dates) under the applicable Plan and remain subject to the agreement pursuant to which your original IVAX Option was granted. In connection with the conversion, new trading accounts must be established with Merrill Lynch. All current option holders must complete the enclosed Stock Option Exercise and Sell Account Form in order to open an account with Merrill Lynch. Submission of the completed form by itself does not indicate your intention to exercise your options or to sell the resulting stock at this time. Option holders who do not open an account with Merrill Lynch will not be able to exercise options after the merger completion date until an account is opened. The attached procedure for exercising options will be in effect upon the completion of the merger transaction, subject to any blackout periods in connection with the conversion of IVAX options to Teva options. Please review the enclosed procedure and complete the Option Exercise and Sell Account Form and return it to Merrill Lynch to expedite the establishment of your new stock option account. Sincerely, /s/ Joyce L. Hawkins Joyce L. Hawkins Senior Director, Shared Services Human Resources -----END PRIVACY-ENHANCED MESSAGE-----